MEDLINE Journals

    Clinical features that discriminate inhalational anthrax from other acute respiratory illnesses.

    Authors

    Kuehnert MJ, Doyle TJ, Hill HA, et al. 

    Institution

    Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Atlanta, GA 30333, USA. mkuehnert@cdc.gov

    Source

    Clin Infect Dis 2003 Feb 1; 36(3) :328-36.

    Abstract

    Inhalational anthrax (IA) is a rapidly progressive disease that frequently results in sepsis and death, and prompt recognition is critical. To distinguish IA from other causes of acute respiratory illness, patients who had IA were compared with patients in an ambulatory clinic who had influenza-like illness (ILI) and with hospitalized patients who had community-acquired pneumonia (CAP) at the initial health care visit. Compared with patients who had ILI, patients who had IA were more likely to have tachycardia, high hematocrit, and low albumin and sodium levels and were less likely to have myalgias, headache, and nasal symptoms. Scoring systems were devised to compare IA with ILI or CAP on the basis of strength of association. For ILI, a score of > or =4 captured all 11 patients with IA and excluded 664 (96.1%) of 691 patients with ILI. Compared with patients who had CAP, patients with IA were more likely to have nausea or vomiting, tachycardia, high transaminase levels, low sodium levels, and normal white blood cell counts. For CAP, a score of > or =3 captured 9 (81.8%) of 11 patients with IA and excluded 528 (81.2%) of 650 patients with CAP. In conclusion, selected clinical features of patients with IA differ from those of patients with ILI and are more similar to those of patients with CAP.

    Mesh

    Acute Disease
    Albumins
    Anthrax
    Headache
    Hematocrit
    Humans
    Inhalation Exposure
    Middle Aged
    Respiratory Tract Infections
    Tachycardia

    Language

    eng

    Pub Type(s)

    Journal Article

    PubMed ID

    12539075

    Content Manager
    Related Content

    Death due to bioterrorism-related inhalational anthrax: report of 2 patients.

    Considerations for distinguishing influenza-like illness from inhalational anthrax.

    Accuracy of screening for inhalational anthrax after a bioterrorist attack.

    Clinical predictors of bioterrorism-related inhalational anthrax.

    Features discriminating SARS from other severe viral respiratory tract infections.

    Discriminating inhalational anthrax from community-acquired pneumonia using chest radiograph findings and a clinical algorithm.

    Inhalational anthrax due to bioterrorism: would current Centers for Disease Control and Prevention guidelines have identified the 11 patients with inhalational anthrax from October through November 2001?

    Do influenza and acute respiratory infective diseases weigh heavily on general practitioners' daily practice?